I had a great time discussing the USDA’s hemp regulations with John Kagia and Jake Sitler on April 22, 2020. The webinar was hosted by New Frontier Data. You can watch it here.
Category: Products
Do Not Claim That Your CBD Helps With COVID-19
It is good to see the FDA taking quick and firm action against companies improperly marketing their CBD products as effective against COVID-19, a devastating pandemic with no contemporary precedent.
Cannabis Impairment and Driving: Legal and Medical Considerations
The notion that impairment can be assumed or not based solely on specific concentrations of THC or its metabolites in a driver’s blood or urine is plainly wrong.
Want to Read the Latest Edition of the American Journal of Endocannabinoid Medicine?
The American Journal of Endocannabinoid Medicine (AJEM) is the only printed, peer-reviewed, medical cannabis journal in North America. AJEM’s mission is to create, collect, and disseminate credible cannabis research data.
Are Oregon Cannabis Dispensaries Offering an Essential Service?
If cannabis stores close, the state of Oregon would be depriving many patients who rely on retail cannabis stores access to their medicine. If retail cannabis stores remain open, does it make sense to limit access to medicinal patents?
Hemp Trademarking- Why You Cannot Own a Varietal Name
Trademark registration is not simply a matter of racing to the USPTO to register a word or phrase that you wish to have exclusive rights to, even if you were the first to use the word or phrase.
Concerned About Coronavirus and Your Cannabis Business? We’d Like to Help.
As a service to our current clients and readers during these difficult times, we are offering a free 20-minute phone call to address your pressing issues – no strings attached.
Rod Discusses US and EU CBD Regulations at Europe Canna Expo-Dublin
For my talk, I compared and contrasted the hemp and CBD regulatory regimes in Europe and US. Although they parallel each other in some respects, particularly policy, they are fundamentally different in their approaches.
FDA Responds to Congress and Seeks Guidance About CBD
The FDA has yet to create a regulatory pathway for CBD. Does its most recent report to Congress herald a change?